CJC-1295 DAC (2 mg Vial) & Ipamorelin (5 mg Vial) Dosage Protocol
GHRH analog (CJC-1295 DAC) + ghrelin-receptor GH secretagogue (Ipamorelin) — two separate research-only vials; the combination is not clinically validated.
Fixed ratio: CJC-1295 DAC 2 mg : Ipamorelin 5 mg — a 2:5 blend. Every withdrawal keeps that ratio, so the components cannot be dosed independently.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure CJC-1295 DAC + Ipamorelin · 2 mg
Dosing & Reconstitution Guide
Each peptide reconstituted in its own vial — CJC-1295 DAC dosed in mg, Ipamorelin in mcg
CJC-1295 DAC (2 mg Vial): Standard / Gradual Approach (1 mL = 2 mg/mL)
Reconstitute: Add 1.0 mL bacteriostatic water to the 2 mg vial → final concentration 2 mg/mL (20 mcg/unit). Each full vial = 2 mg total.
Typical weekly total: 1 mg per week, given as one injection (or split into 2).
Easy measuring: At 2 mg/mL, 0.5 mg ≈ 25 units (0.25 mL) and 1 mg ≈ 50 units (0.5 mL) on a U-100 syringe.
To split for smoother IGF-1 levels, administer 0.5 mg (25 units) twice weekly.
CJC-1295 DAC (2 mg Vial): Advanced / Aggressive Approach (1 mL = 2 mg/mL)
Reconstitute: Add 1.0 mL bacteriostatic water to the 2 mg vial → 2 mg/mL (20 mcg/unit). The full vial delivers a single 2 mg weekly dose.
Easy measuring: At 2 mg/mL, 2 mg ≈ 100 units (1 mL) and 1 mg ≈ 50 units (0.5 mL) on a U-100 syringe.
Alternatively, split into 1 mg (50 units) twice weekly. Draw 1.0 mL of bacteriostatic water along the vial wall, swirl gently (do not shake), and store at 2–8 °C protected from light; use within 30 days and do not freeze.
Ipamorelin (5 mg Vial): Recommended Approach (2 mL = 2.5 mg/mL)
Reconstitute: Add 2.0 mL bacteriostatic water to the 5 mg vial → concentration 2.5 mg/mL (25 mcg/unit), improving small-dose accuracy.
Easy measuring: At 2.5 mg/mL, 200 mcg ≈ 8 units (0.08 mL) and 300 mcg ≈ 12 units (0.12 mL) on a U-100 syringe.
Daily dosing typically runs 200–300 mcg (8–12 units) as a single injection. Draw 2.0 mL of bacteriostatic water along the vial wall, swirl gently until dissolved, and refrigerate at 2–8 °C protected from light; discard after 30 days or if cloudy. If your injection volume falls below ~10 units, a smaller (50-unit) syringe improves precision.
Many researchers run these peptides together on the same protocol day for potentially enhanced GH release: CJC-1295 DAC at 1–2 mg/week (1–2 injections) and Ipamorelin at 200–300 mcg/day (1 daily injection). Reconstitute each peptide in its own vial and never combine them into the same syringe. Use separate syringes and injection sites. This combined protocol is not clinically validated.
Why CJC-1295 DAC + Ipamorelin draws research interest
These are the directions researchers and the peptide community most often explore CJC-1295 DAC + Ipamorelin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
GH & IGF-1 support
CJC-1295 DAC is a GHRH analog investigated in early-phase human trials for sustained GH and IGF-1 elevation; not approved.
Fat metabolism / lipolysis
Explored in research on GH-driven lipolysis and fat metabolism; based on animal and early human data only, no approved use.
Body composition / lean mass
Studied as a GH secretagogue for effects on lean mass and body composition; investigational and not clinically validated.
Sleep & recovery
Investigated for links between GH-axis stimulation and slow-wave sleep; preclinical and small-study evidence only.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Supplies Needed
Basic materials for a typical 4–6 week research cycle. Adjust total vials based on dosage and cycle length.
One separate vial, reconstituted on its own. At 1–2 mg/week, a 2 mg vial covers roughly 1–2 weeks of dosing.
One separate vial, reconstituted on its own. At ~200–300 mcg/day, a 5 mg vial covers roughly 16–25 days of dosing.
One new sterile syringe per injection (30–100 unit size). Use a separate syringe for each peptide.
1× 30 mL bacteriostatic water (or as needed) and one box of alcohol swabs for stoppers and injection sites.
Important Notes
Tips for safe, consistent research usage across the two-vial stack.
Important: Neither CJC-1295 DAC nor Ipamorelin is FDA-approved; both are unapproved research chemicals (assigned 503A Category 2 and difficult to compound). The “synergy” of the stack is theorized, not proven. Before viewing any protocol, please consult our Prep & Injection Guide for essential preparation and safety instructions.
- ▪Sterile technique: Use new, sterile insulin syringes for each injection and rotate injection sites.
- ▪Never mix: Never combine CJC-1295 DAC and Ipamorelin in the same syringe; reconstitute each in its own vial.
- ▪Consistency: Maintain a consistent protocol; peptides often show best outcomes with regular dosing.
- ▪Monitoring: Monitor for adverse reactions; consult a professional if concerns arise.
- ▪Regulatory note: Both peptides are not FDA-approved and are prohibited by WADA at all times (class S2) for athletic use[6].
How This Works
CJC-1295 DAC and Ipamorelin both target the growth-hormone (GH) axis, but through different mechanisms.
CJC-1295 DAC is a long-acting GHRH(1–29) analog; its Drug Affinity Complex (DAC) binds serum albumin, giving it a multi-day half-life and sustained GH release with elevated IGF-1 over time[1][3].
Ipamorelin is a selective ghrelin / GHS-R agonist — a GH secretagogue known for triggering a clean GH pulse with minimal effect on cortisol or prolactin[2].
The rationale for stacking a GHRH analog with a ghrelin-receptor agonist is a theorized synergy: sustained GH elevation (from CJC-1295) plus consistent GH peaks (from Ipamorelin). This proposed synergy and the specific doses here are not clinically validated, and neither compound has approved human use.
Lifestyle Factors
Complementary strategies that may support outcomes alongside the protocol.
- ▪Nutrition: Maintain a protein-rich diet and stay well hydrated.
- ▪Activity & rest: Engage in regular exercise and allow adequate rest and recovery.
- ▪Sleep: Prioritize quality sleep, which supports the natural GH/IGF-1 axis[4].
- ▪Stress: Manage stress with evidence-based practices.
Potential Benefits & Side Effects
Research explores various benefits, with caution for side effects; human evidence for this combination is limited and results vary.
Potential Benefits
- ▪GH / IGF-1 (theorized): Increased GH and IGF-1 may support tissue repair in certain models.
- ▪Recovery (preclinical): Possible support for muscle repair, injury recovery and collagen synthesis.
- ▪Note on humans: These benefits are not established for this combination — no approved human use and no validation of the stack.
Common Side Effects
- ▪Mild reactions: Possible injection-site irritation, water retention or headaches.
- ▪Unknown long-term profile: Long-term safety and efficacy continue to be investigated; human safety data is limited.
- ▪Sport restriction: Both peptides are WADA-prohibited (class S2) at all times.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[7][8]. Apply the same steps to each vial, using a separate syringe per peptide.
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe each vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[8].
- ▪Draw the intended dose for that peptide, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[7].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[7].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return each reconstituted vial to the fridge right away.
- ▪Rotate the injection site each time to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for both CJC-1295 DAC and Ipamorelin.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
Journal of Clinical Endocrinology & MetabolismProlonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults.
- 2
European Journal of EndocrinologyIpamorelin, the first selective growth hormone secretagogue, with minimal effect on cortisol and prolactin.
- 3
Endocrine ReviewsGrowth hormone secretagogues: mechanisms of action and clinical applications.
- 4
Sleep Medicine ReviewsSleep and the GH/IGF-1 axis: physiological and clinical implications.
- 5
BachemHandling and storage guidelines for peptides (lyophilized and reconstituted stability).
- 6
World Anti-Doping Agency (WADA)Prohibited List — class S2 (peptide hormones, growth factors and GH secretagogues), prohibited at all times.
- 7
CDCVaccine administration guidelines: subcutaneous route and injection angle (no aspiration required).
- 8
NCBI BookshelfParenteral medication administration: subcutaneous injection technique.
- 9
Diabetes Therapy (PMC)Injection-site rotation and prevention of lipohypertrophy in subcutaneous administration.
How to reconstitute CJC-1295 DAC + Ipamorelin
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the CJC-1295 DAC + Ipamorelin vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
CJC-1295 DAC + Ipamorelin — frequently asked questions
How do I reconstitute a 2 mg vial of CJC-1295 DAC + Ipamorelin?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to CJC-1295 DAC + Ipamorelin?
There is no single correct amount — more water simply spreads the same 2 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store CJC-1295 DAC + Ipamorelin after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 2 mg vial of CJC-1295 DAC + Ipamorelin provide?
Divide the vial strength of 2 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is CJC-1295 DAC + Ipamorelin approved for human use?
No. CJC-1295 DAC + Ipamorelin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.